5% 5‑fluorouracil with or without 15% aluminum chloride for actinic keratoses
Official title: Actinic Keratoses Treated With 5-fluorouracil Plus Aluminum: an Exploratory Study
Run by West Virginia University · NCT07401277 · Data updated 2026-11-12
This will see if adding 15% aluminum chloride to 5% 5‑fluorouracil cream helps clear actinic keratoses on the scalp or forearms in adults with 4–15 lesions after one week of treatment.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 50 Years |
| Sex | All |
| Enrollment | 32 (estimated) |
| Sponsor | West Virginia University Academic / other |
| Drugs / interventions | Chemotherapy |
| Locations | 1 site (Morgantown, West Virginia) |
| Status | Recruiting |
| Started | February 6, 2026 |
| Main results expected | July 2027 |
| Study ends | August 2027 |
| Registry record updated | April 22, 2026 |
| Trial ID | NCT07401277 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 50 or older with 4–15 clinically diagnosed actinic keratoses on the scalp or forearms, ECOG performance status ≤2, who can provide informed consent and attend visits at WVU are ideal candidates.
✕Probably not a fit
People with suspected squamous cell or basal cell carcinoma or open wounds at the treatment site, known allergy to aluminum chloride, recent use of specified topical or systemic therapies, immunosuppression, or those under age 50 are unlikely to qualify or benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This single-center Phase 1 study at West Virginia University compares two topical regimens for actinic keratoses: 5% 5‑fluorouracil alone versus 5% 5‑fluorouracil combined with 15% aluminum chloride hexahydrate. Participants aged 50 and older with 4–15 clinically diagnosed AKs on the scalp or forearms will apply the assigned cream for one week. Dermatologists will count lesions and take photographs before and shortly after treatment to document response and monitor safety. The trial is intended to generate early signals about tolerability and short-term lesion clearance rather than provide definitive efficacy results.
Why it matters
Potential benefit: If successful, adding aluminum chloride could increase short-term clearance of actinic keratoses and reduce the need for additional procedures.
How similar studies have gone: Topical 5‑fluorouracil is an established treatment for actinic keratoses, but combining it with aluminum chloride hexahydrate is a novel approach with little published data on clinical benefit.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Less than 50 years due to this being a pathology of adults that develops in chronically sun-damaged skin, individuals \<50 years of age are excluded from this study. * Patients with 4-15 clinically diagnosed AKs on the scalp (16 patients) or on the forearms (16 patients) being followed at the Mohs Surgery clinic by WVU Medicine Dermatology * Performance status: ECOG Performance status less than or equal to 2 * Patient must provide informed consent Exclusion Criteria: * Presence of a suspected squamous cell carcinoma (SCC) or basal cell carcinoma (BCC) lesion or open wound on the treatment site (scalp or forearm) * History of allergic reactions attributed to compounds of similar chemical or biologic composition to 15% ACH or other agents used in this study * Use of one or more of the following products within the past month: * Tanning skin colorants * Prescription topical drugs * Immunomodulatory or immunosuppressive medicines * Chemotherapy or cytotoxic medications * Photodynamic therapy (PDT) or other treatments of pre-cancers on the skin * Vitamin A derivatives taken by mouth * Patients receiving any other investigational agents * Patients with immunosuppression or weakened immune systems who may be at a higher risk of infection, including patients who have had chronic lymphocytic leukemia (CLL), who have received transplants, or who are taking medications such as chronic steroids or rheumatoid arthritis (RA) drugs
Where it's running
-
West Virginia University
Morgantown, West Virginia, United States Recruiting
Study contacts
- Principal investigator: Joanna Kolodney, MD — West Virginia University
- Study coordinator: Vlad Codrea, MD, PhD
- Email: vlad.codrea@hsc.wvu.edu
- Phone: 304-598-4548
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using laser treatment to prevent skin cancer in older adults with precancerous lesions
This study tests if a special laser treatment can help older adults with precancerous skin spots avoid developing skin cancer.
-
Effect of Lipikar Baume AP+M on Actinic Keratoses
This study is testing whether using Lipikar Baume AP+M can help improve skin health in adults with actinic keratoses caused by sun damage.
-
Using Optical Coherence Tomography to Diagnose Oral Cancer
This study is testing if a special imaging technique called Optical Coherence Tomography can help doctors find oral cancer earlier and more accurately in patients with potentially harmful mouth conditions.
-
Using laser treatment to protect older skin from skin cancer
This study tests if a special laser treatment can help older adults with actinic keratosis reduce their chances of developing skin cancer in the future.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.